Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Aug 21, 2018 (8 years ago)

Oxycodone and Acetaminophen Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect or Missing Lot and/or Exp Date: Lot FG10517 is mislabeled on the primary container with Lot FG01517, shipper labels and invoices contain the correct lot number of FG10517.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Oxycodone and Acetaminophen Tablets, USP, 5 mg*/325 mg, 100-count bottle, Rx Only, Manufactured by: Mayne Pharma, Greenville, NC 27834, NDC 68308-841-01.

Affected NDC 68308-0841-01

Compare with the code on your package — it is the most precise check available.

Drug: Acetaminophen Category: Pain Relief & OTC Medication

Recalling firm
Mayne Pharma Inc
NDC code
68308-841-01
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1129-2018 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Acetaminophen recalls

See all
Class II · Moderate risk

Tylenol

Defective Container

Ongoing Packaging defect Kenvue Brands LLC D-0121-2026
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026

Other recalls by Mayne Pharma Inc

All 2018 recalls
Class II · Moderate risk

Clonidine Transdermal System

Defective Delivery System: Out of specification for release liner removal force results at the 3-month CRT stability timepoint.

Terminated Packaging defect Mayne Pharma Inc NDC 51862-455-01 D-1152-2022
Class II · Moderate risk

Lexette (halobetasol propionate)

CGMP Deviation: Difficulty dispensing/does not dispense or dispensing liquid instead of foam.

Ongoing cGMP deviation Mayne Pharma Inc NDC 51862-604-50 D-0387-2022
Class III · Low risk

Fabior (tazarotene)

Superpotent Drug: High out of specification results for tazarotene assay at the 9-month stability time point.

Terminated Wrong potency / content Mayne Pharma Inc NDC 51862-295-10 D-0616-2018